Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 17, 2026Reported sale · Form 4RA CAPITAL MANAGEMENT, L.P. · $21.6MOpen the filing ↗
- Sep 17, 2026Reported sale · Form 4RA CAPITAL MANAGEMENT, L.P. · $252.1KOpen the filing ↗
- Sep 17, 2026Notice of sale · Form 144RA Capital Healthcare Fund, L.P. · Director, 10% Stockholder · $21.8MOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year201
SEC filings on record21924 flagged findings
Reported transactions (Form 4)80since Jun 12, 2025 · and 39 other holdings
Corporate events (8-K)2since Sep 14, 2026
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-12share offering or dilution eventrecentOpen filing ↗“…31, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial…”
- 2026-05-12listing compliance noticerecentOpen filing ↗“…price and trading volume to decline. We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing…”
+1 more passage from the same document
- “…of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. Since our common stock is listed on Nasdaq, we must meet…”
- 2026-05-12regulatory investigationrecentOpen filing ↗“…Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may…”
+1 more passage from the same document
- “…thereto) submitted by us or our strategic partners; • restrict the marketing or manufacturing of the drug; • seize or detain the…”
- 2026-05-12Department of Justice inquiryrecentOpen filing ↗“…to comply with them. Additionally, through executive and legislative action, the federal government has taken steps to restrict…”
- 2026-03-02share offering or dilution eventrecentOpen filing ↗“…exercise; • in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise…”
+1 more passage from the same document
- “…investments in marketable securities to in-license, acquire or invest in complementary businesses, technologies, products or…”
- 2026-03-02listing compliance noticerecentOpen filing ↗“…price and trading volume to decline. We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing…”
+1 more passage from the same document
- “…of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. Since our common stock is listed on Nasdaq, we must meet…”
- 2026-03-02capital return (buybacks/dividends)recentOpen filing ↗“…for forfeitures when they occur. Stock-based compensation expense is classified in the accompanying consolidated statements of…”
- 2026-03-02regulatory investigationrecentOpen filing ↗“…Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may…”
+1 more passage from the same document
- “…by us or our strategic partners; • restrict the marketing or manufacturing of the drug; 93 Table of Contents • seize or detain the…”
1 older entry not shown
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 219)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 21, 26SCHEDULE 13D/A ↗Stake with intent to influence · RA Capital Management, L.P. · 14.3% · event on Sep 17, 26 · amendment
- Sep 17, 26Form 144 ↗Notice of proposed sale
- Sep 14, 268-K ↗Current report · Restructuring plan with committed costs
- Aug 10, 268-K ↗Current report · Other events
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Jul 6, 26Form 144 ↗Notice of proposed sale
Insider transaction · 7 Form 4 filingsshow all 7hide
- Jun 18, 268-K ↗Current report · Shareholder vote results
219 filings on record, the oldest from Oct 10, 24.
Listing the 25 most recent filings of the 219 on record.
11
- Sep 14, 26Restructuring plan with committed costs+3 more in the same filing8-K 2.05 ↗
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- TPG GP A, LLC15.2%Feb 10, 25SCHEDULE 13D ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
- RA Capital Management, L.P.14.3%Sep 17, 26SCHEDULE 13D/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- ORBIMED ADVISORS LLC6.6%Apr 15, 26SCHEDULE 13D/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Enavate Sciences GP, LLC5.6%Feb 10, 25SCHEDULE 13D ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
- Atlas Venture Fund XI, L.P.5.4%Oct 16, 25SCHEDULE 13D/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- VIKING GLOBAL INVESTORS LP7.1%Mar 31, 26SCHEDULE 13G/A ↗10 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Qatar Investment Authority4.5%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- JPMORGAN CHASE & CO.4.4%Sep 30, 25SCHEDULE 13G/A ↗1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Sep 17, RA Capital Healthcare Fund, L.P. filed notice of intent to sell up to $21.8M. That is about 7.63% of shares outstanding.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
No sale of theirs is on record yet in Form 4; the 90-day window is still open.
View notice (Form 144) ↗+1 more recent notices · 1 with a later sale
- Sep 17, 26Sell$21.6MRA CAPITAL MANAGEMENT, L.P.↗
- Sep 17, 26Sell$252KRA CAPITAL MANAGEMENT, L.P.↗
- Jul 7, 26Sell$3.9MORBIMED ADVISORS LLC↗
- Jul 6, 26Sell$447KJennifer FitzpatrickChief Legal Officer↗
- Jun 30, 26Sell$5.3MORBIMED ADVISORS LLC↗
- May 27, 26Sell$4KORBIMED ADVISORS LLC↗
- May 11, 26Sell$8.5MORBIMED ADVISORS LLC↗
- May 8, 26Sell$2.7MORBIMED ADVISORS LLC↗
- May 7, 26Sell$2.2MORBIMED ADVISORS LLC↗
- Apr 18, 26Sell$131KORBIMED ADVISORS LLC↗
- Apr 17, 26Sell$2.3MORBIMED ADVISORS LLC↗
- Apr 16, 26Sell$10.3MORBIMED ADVISORS LLC↗
There are 17 more transactions in this stretch.
Stock compensation, tax and giftsshow the 11 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 17, 26Compensationamount n/aMichael CloonanPresident & CEO↗
- Sep 17, 26Compensationamount n/aMichael CloonanPresident & CEO↗
- Sep 17, 26Compensationamount n/aElena RidloffCFO and CBO↗
- Sep 17, 26Compensationamount n/aElena RidloffCFO and CBO↗
- Sep 17, 26Compensationamount n/aCharlotte McKeeCMO and Head of R&D↗
- Sep 17, 26Compensationamount n/aCharlotte McKeeCMO and Head of R&D↗
- Sep 17, 26Compensationamount n/aJennifer FitzpatrickCLO and Head of Program Mgmt.↗
- Sep 17, 26Compensationamount n/aJennifer FitzpatrickCLO and Head of Program Mgmt.↗
- Jul 6, 26Compensation$63KJennifer FitzpatrickChief Legal Officer↗
- Mar 5, 26Compensation$63KJennifer FitzpatrickChief Legal Officer↗
- Dec 5, 25Compensation$63KJennifer FitzpatrickChief Legal Officer↗
The full record holds 181 transactions and goes back to Feb 6, 25.
Its sector and its market
Sionna Therapeutics Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Sionna Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Sionna Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 219 documents on file, from Oct 10, 2024 to Sep 21, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.